PARIS, June 23. /TASS/. by the French pharmaceutical Corporation Sanofi plans to begin clinical trials of a vaccine against the new coronavirus in September this year and release it in the sale in the first half of 2021. This is stated in a statement on Tuesday the statement of the Corporation.
Sanofi assures that the vaccine is “effective and reliable” and will be produced in large volumes.
As noted by General Director of Sanofi Paul Hudson, speaking of strong competition in the sphere of creation of vaccines against coronavirus, his company “has a slower than competitors, but at the same time has great chances to succeed than they are.”
we are Talking about the vaccine, jointly developed with the British company GlaxoSmithKline and is based on the technology of DNA recombination, which is already applied when you create antigrippoznyh vaccines.
At Sanofi believe that the Corporation in case of successful completion of vaccine trials, can produce up to 1 billion doses a year.
at the same time Sanofi is developing another vaccine against coronavirus in cooperation with the biotech company Translate Bio. This vaccine is created by transfer of a fragment of RNA, the genetic code of the virus. This vaccine clinical trials the first phase scheduled for the period until the end of the year. In case of success, the company hopes to certify it in the second half of 2021 and to produce in the future, from 90 million to 360 million doses per year.